Back in May, we noted that 2003 saw Big Pharma receive, for the first time, more drug approvals for in-licensed drugs than for those it had developed internally (See "In-Licensing Pays Off for Big Pharma," IN VIVO, May 2004 [A#2100480096].) In 2004, the pendulum has swung the other way for Big Pharma: just 6 of its 15 approvals were for in-licensed drugs. For the industry in general, in-licensing still accounts for more than half of the approvals: 16 of the 30 new drugs (including Big Pharma's) were in-licensed. The ratio would have been the same even not counting the late-December approvals of Pfizer Inc. 's pregabalin (Lyrica), acquired with Warner-Lambert; Novartis AG 's darifenacin (Enablex), which Pfizer sold in March 2003 to avoid antitrust violations [See Deal]; Elan Corp. PLC 's own ziconotide (Prialt); CoTherix Inc. 's iloprost (Ventavis), licensed from Schering AG [See Deal]; and Genzyme Corp. 's clofarabine (Clolar), licensed from Bioenvision Inc. via Genzyme's Ilex Oncology Inc. [See Deal].
Among Big Pharma's most productive pipelines were Sanofi-Aventis SA 's, which saw the approvals of internally developed telithromycin (Ketek)...





